Fosun Pharma continues to uphold the internationalization strategy in multiple dimensions, such as innovative R&D, licensing, manufacturing and operations as well as commercialization. In 2024, ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...

Yet today, at what should be a celebration of this revolutionary technology’s potential, we find ourselves wondering about the future of mRNA research. The scientific community is watching if funding ...

Many consumers might be surprised to learn that their daily products – from Shimla and Kashmiri apples to pharmaceutical ...

Experts underestimated Trump's seriousness on tariffs; Indian auto and pharma sectors brace for impact, while steel remains ...

US pharma giants eye India’s obesity crisis with pricey shots, sparking ‘Make in India’ and affordability debates ...

India's obesity crisis is intensifying, with big pharma companies like Eli Lilly and Novo Nordisk competing to introduce ...

The drug will be priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for the 5 mg vial. The injectable, to be taken once a week, ...

FIIs have been steering their focus from large-cap stocks to select small-cap names, signaling a change in market dynamics.

The inspection comes after a ProPublica investigation revealed that drugs made at the Glenmark Pharmaceuticals plant ...

Starting at Rs 3,500 per injection, with a monthly cost of up to Rs 14,000, Mounjaro enters India’s growing diabetes and ...

HYDERABAD (Reuters) -Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating ...